Glyscend Incorporated

Glyscend Incorporated

Glyscend Incorporated

Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes.
Founded
2014
Raised
$21M
Follow us
Alexa global traffic share
Latest funding
$20,500,000
Venture capital (Series A) - 2020
Sante Ventures Brandon Capital Partners
$500,000
Grant - 2016
Johnson & Johnson Innovation
Team Size
2
Employees
$20,500,000 Venture capital (Series A)
FinSMEs

Glyscend Therapeutics Closes $20.5M Series A Financing Round